United States - English - NLM (National Library of Medicine)

camber pharmaceuticals, inc. - lenalidomide (unii: f0p408n6v4) (lenalidomide - unii:f0p408n6v4) - lenalidomide capsules in combination with dexamethasone are indicated for the treatment of adult patients with multiple myeloma (mm). lenalidomide capsules are indicated as maintenance therapy in adult patients with mm following autologous hematopoietic stem cell transplantation (auto-hsct). lenalidomide capsules are indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. lenalidomide capsules are indicated for the treatment of adult patients with mantle cell lymphoma (mcl) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib.  lenalidomide capsules in combination with a rituximab product, is indicated for the treatment of adult patients with previously treated follicular lymphoma (fl).  lenalidomide capsules in combination with a rituximab product, is indicated for

Canada - English - Health Canada

teva canada limited - lenalidomide (lenalidomide hydrochloride monohydrate) - capsule - 2.5mg - lenalidomide (lenalidomide hydrochloride monohydrate) 2.5mg

Canada - English - Health Canada

teva canada limited - lenalidomide (lenalidomide hydrochloride monohydrate) - capsule - 5mg - lenalidomide (lenalidomide hydrochloride monohydrate) 5mg

Canada - English - Health Canada

teva canada limited - lenalidomide (lenalidomide hydrochloride monohydrate) - capsule - 10mg - lenalidomide (lenalidomide hydrochloride monohydrate) 10mg

Canada - English - Health Canada

teva canada limited - lenalidomide (lenalidomide hydrochloride monohydrate) - capsule - 15mg - lenalidomide (lenalidomide hydrochloride monohydrate) 15mg

Canada - English - Health Canada

teva canada limited - lenalidomide (lenalidomide hydrochloride monohydrate) - capsule - 20mg - lenalidomide (lenalidomide hydrochloride monohydrate) 20mg

Canada - English - Health Canada

teva canada limited - lenalidomide (lenalidomide hydrochloride monohydrate) - capsule - 25mg - lenalidomide (lenalidomide hydrochloride monohydrate) 25mg

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - lenalidomide, quantity: 15 mg - capsule - excipient ingredients: gelatin; lactose; shellac; croscarmellose sodium; microcrystalline cellulose; indigo carmine; magnesium stearate; propylene glycol; potassium hydroxide; titanium dioxide; iron oxide black - multiple myeloma (mm),lenalidomide sandoz is indicated for the treatment of multiple myeloma.,myelodysplastic syndromes (mds),lenalidomide sandoz is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.,mantle cell lymphoma (mcl),lenalidomide sandoz is indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - lenalidomide, quantity: 10 mg - capsule - excipient ingredients: lactose; titanium dioxide; iron oxide yellow; gelatin; microcrystalline cellulose; croscarmellose sodium; propylene glycol; shellac; potassium hydroxide; magnesium stearate; indigo carmine; iron oxide black - multiple myeloma (mm),lenalidomide sandoz is indicated for the treatment of multiple myeloma.,myelodysplastic syndromes (mds),lenalidomide sandoz is indicated for treatment of patients with transfusion-dependent anaemia,due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic,abnormality with or without additional cytogenetic abnormalities.,mantle cell lymphoma (mcl),lenalidomide sandoz is indicated for the treatment of patients with relapsed and/or refractory mantle,cell lymphoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - lenalidomide, quantity: 5 mg - capsule - excipient ingredients: magnesium stearate; lactose; potassium hydroxide; propylene glycol; gelatin; titanium dioxide; microcrystalline cellulose; croscarmellose sodium; iron oxide black; shellac - multiple myeloma (mm),lenalidomide sandoz is indicated for the treatment of multiple myeloma.,myelodysplastic syndromes (mds),lenalidomide sandoz is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.,mantle cell lymphoma (mcl),lenalidomide sandoz is indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.